• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches.

作者信息

Perco Paul, Ley Matthias, Kęska-Izworska Kinga, Wojenska Dorota, Bono Enrico, Walter Samuel M, Fillinger Lucas, Kratochwill Klaus

机构信息

Delta4 GmbH, Vienna, Austria.

Department of Internal Medicine IV, Medical University of Innsbruck, Innsbruck, Austria.

出版信息

Proteomics. 2025 Jun;25(11-12):e202400109. doi: 10.1002/pmic.202400109. Epub 2025 Jan 31.

DOI:10.1002/pmic.202400109
PMID:39888210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12205286/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b2/12205286/d4131acf7089/PMIC-25-e202400109-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b2/12205286/dd03b9bddfd1/PMIC-25-e202400109-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b2/12205286/f4e431f593e8/PMIC-25-e202400109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b2/12205286/d4131acf7089/PMIC-25-e202400109-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b2/12205286/dd03b9bddfd1/PMIC-25-e202400109-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b2/12205286/f4e431f593e8/PMIC-25-e202400109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b2/12205286/d4131acf7089/PMIC-25-e202400109-g003.jpg

相似文献

1
Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches.心肾疾病中的计算药物重新定位：机遇、挑战与方法
Proteomics. 2025 Jun;25(11-12):e202400109. doi: 10.1002/pmic.202400109. Epub 2025 Jan 31.
2
Advancements in AI for Computational Biology and Bioinformatics: A Comprehensive Review.用于计算生物学和生物信息学的人工智能进展：全面综述。
Methods Mol Biol. 2025;2952:87-105. doi: 10.1007/978-1-0716-4690-8_6.
3
Tissue fibrosis in cardiorenal syndrome: crosstalk between heart and kidneys.心肾综合征中的组织纤维化：心脏与肾脏之间的相互作用
Nephrol Dial Transplant. 2025 Jan 13. doi: 10.1093/ndt/gfaf009.
4
Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: geneXpharma.转录组学指导的药物重定位得到新生物信息学搜索工具的支持：geneXpharma。
OMICS. 2017 Oct;21(10):584-591. doi: 10.1089/omi.2017.0127.
5
Cardiorenal Syndrome Type 3 Review.心肾综合征 3 型综述。
Cardiol Rev. 2024;32(2):140-145. doi: 10.1097/CRD.0000000000000491. Epub 2022 Oct 10.
6
A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions.计算药物重新定位综述：策略、方法、机遇、挑战及方向
J Cheminform. 2020 Jul 22;12(1):46. doi: 10.1186/s13321-020-00450-7.
7
SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials.钠-葡萄糖协同转运蛋白2抑制剂用于慢性肾脏病患者心肾结局复合终点：一项随机对照试验的系统评价和荟萃分析
Eur J Pharmacol. 2022 Dec 5;936:175354. doi: 10.1016/j.ejphar.2022.175354. Epub 2022 Oct 25.
8
A review of validation strategies for computational drug repositioning.计算药物重定位的验证策略综述。
Brief Bioinform. 2018 Jan 1;19(1):174-177. doi: 10.1093/bib/bbw110.
9
A Review of Drug Repositioning Based Chemical-induced Cell Line Expression Data.基于化学诱导细胞系表达数据的药物重定位综述。
Curr Med Chem. 2020;27(32):5340-5350. doi: 10.2174/0929867325666181101115801.
10
Review of Drug Repositioning Approaches and Resources.药物重定位方法和资源综述。
Int J Biol Sci. 2018 Jul 13;14(10):1232-1244. doi: 10.7150/ijbs.24612. eCollection 2018.

引用本文的文献

1
Integrative Analysis of Drug Co-Prescriptions in Peritoneal Dialysis Reveals Molecular Targets and Novel Strategies for Intervention.腹膜透析中药物联合处方的综合分析揭示了分子靶点和新的干预策略。
J Clin Med. 2025 May 26;14(11):3733. doi: 10.3390/jcm14113733.

本文引用的文献

1
Exploring antidiabetic drug targets as potential disease-modifying agents in osteoarthritis.探索抗糖尿病药物靶点作为骨关节炎潜在的疾病修饰治疗药物。
EBioMedicine. 2024 Sep;107:105285. doi: 10.1016/j.ebiom.2024.105285. Epub 2024 Aug 16.
2
The benefits of GLP-1 drugs beyond obesity.胰高血糖素样肽-1（GLP-1）药物在治疗肥胖症之外的益处。
Science. 2024 Jul 19;385(6706):258-260. doi: 10.1126/science.adn4128. Epub 2024 Jul 18.
3
Reliable business case for repurposing of existing medicines requires key changes in government policies.重新利用现有药物的可靠商业案例需要政府政策做出关键改变。
Drug Discov Today. 2024 Sep;29(9):104096. doi: 10.1016/j.drudis.2024.104096. Epub 2024 Jul 9.
4
Identification of novel therapeutic targets for chronic kidney disease and kidney function by integrating multi-omics proteome with transcriptome.通过整合多组学蛋白质组学和转录组学，鉴定慢性肾脏病和肾功能的新治疗靶点。
Genome Med. 2024 Jun 19;16(1):84. doi: 10.1186/s13073-024-01356-x.
5
Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease.计算药物发现方法确定甲苯咪唑为常染色体显性多囊肾病的候选治疗药物。
Front Pharmacol. 2024 May 23;15:1397864. doi: 10.3389/fphar.2024.1397864. eCollection 2024.
6
Drugst.One - a plug-and-play solution for online systems medicine and network-based drug repurposing.Drugst.One - 一种即插即用的在线系统医学和基于网络的药物再利用解决方案。
Nucleic Acids Res. 2024 Jul 5;52(W1):W481-W488. doi: 10.1093/nar/gkae388.
7
Amantadine interactions with phase separated lipid membranes.金刚烷胺与相分离脂质膜的相互作用。
Chem Phys Lipids. 2024 Aug;262:105397. doi: 10.1016/j.chemphyslip.2024.105397. Epub 2024 May 11.
8
Statins as anti-tumor agents: A paradigm for repurposed drugs.他汀类药物作为抗肿瘤药物：重新定位药物的范例。
Cancer Rep (Hoboken). 2024 May;7(5):e2078. doi: 10.1002/cnr2.2078.
9
Applications of SGLT2 inhibitors beyond glycaemic control.SGLT2 抑制剂在血糖控制之外的应用。
Nat Rev Nephrol. 2024 Aug;20(8):513-529. doi: 10.1038/s41581-024-00836-y. Epub 2024 Apr 26.
10
Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design.氯吡格雷用于减少局灶节段性肾小球硬化症蛋白尿：2期试验设计
Kidney Int Rep. 2023 Nov 3;9(2):478-481. doi: 10.1016/j.ekir.2023.10.027. eCollection 2024 Feb.